Skip to main content

Calyptus receives FDA nod for generic Brovana

Generic Brovana is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Levy

The Food and Drug Administration has given the green light to Calyptus’ partner, Vista Pharm, for a generic version of Brovana (arformoterol tartrate inhalation solution, EQ 0.015 mg base/2 ml). Calyptus co-developed the product in collaboration with VistaPharm.

Generic Brovana is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.

[Read more: AAM report: Generics, biosimilars saved U.S. healthcare system $8B in 2020

Arformoterol tartrate inhalation solution is for use by nebulization only, the company noted.

"We are thrilled with this approval in partnership with VistaPharm,” Calyptus co-founders Sujeet Singh, Puiho Yuen and Shubhayu Sinharoy said. “We believe that combining Calyptus' know-how and expertise with partners is key to bringing affordable medicines to patients and creating shared success. The successful development, and approval of a generic formulation of arformoterol tartrate inhalation solution is a testimony to these efforts.”

[Read more: Challenges continue, but generics companies see a bright future with biosimilars]

Arformoterol tartrate inhalation solution had a market value of approximately $104 million for the 12 months ending June 2022, according to IQVIA.

X
This ad will auto-close in 10 seconds